Provided by Tiger Trade Technology Pte. Ltd.

RxSIGHT, INC.

6.40
+0.14002.24%
Volume:366.35K
Turnover:2.31M
Market Cap:264.94M
PE:-5.62
High:6.41
Open:6.23
Low:6.14
Close:6.26
52wk High:13.22
52wk Low:4.48
Shares:41.40M
Float Shares:33.77M
Volume Ratio:0.46
T/O Rate:1.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1385
EPS(LYR):-0.9533
ROE:-17.35%
ROA:-10.41%
PB:1.01
PE(LYR):-6.71

Loading ...

RxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales Outlook

GlobeNewswire
·
May 07

Rxsight Inc expected to post a loss of 28 cents a share - Earnings Preview

Reuters
·
May 05

RxSight announces annual shareholder meeting via virtual webcast

Reuters
·
Apr 29

RxSight to report first-quarter results after market close May 6

Reuters
·
Apr 23

RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6

GlobeNewswire
·
Apr 23

RxSight highlights ASCRS data showing 91.2% LAL accuracy within 0.50 diopters

Reuters
·
Apr 09

RxSight Highlights 300,000 Light Adjustable Lens Implant Milestone and Strong Scientific Presence at ASCRS 2026

GlobeNewswire
·
Apr 09

RxSight to join Needham Virtual Healthcare Conference fireside chat

Reuters
·
Apr 03

RxSight amends CFO appointment filing to disclose USD 169,348 sign-on bonus

Reuters
·
Mar 20

RxSight Earnings Call: Strong Core, Cautious Outlook

TIPRANKS
·
Mar 09

Analysts Have Conflicting Sentiments on These Healthcare Companies: Silence Therapeutics (SLN), RxSight (RXST) and Compass Therapeutics (CMPX)

TIPRANKS
·
Mar 06

Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), BioLife Solutions (BLFS) and RxSight (RXST)

TIPRANKS
·
Feb 27

UBS Adjusts Price Target on RxSight to $9 From $8, Maintains Neutral Rating

MT Newswires Live
·
Feb 26

RxSight price target raised to $9 from $8 at UBS

TIPRANKS
·
Feb 26

RxSight Price Target Maintained With a $13.00/Share by Needham

Dow Jones
·
Feb 26

Wells Fargo Remains a Hold on RxSight (RXST)

TIPRANKS
·
Feb 26

Rxsight Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Feb 26

RxSight Q4 revenue falls 19% on lower LDD sales

Reuters
·
Feb 26

RxSight Q4 Adj. EPS $(0.03) Beats $(0.33) Estimate, Sales $32.607M Beat $30.117M Estimate

Benzinga Earnings
·
Feb 26

BRIEF-Rxsight Q4 Gross Profit USD 25.3 Million

Reuters
·
Feb 26